Novanta Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NOVT research report →
Range $194 – $194
Price Chart
About the company
Operating globally, Novanta Inc. and its affiliated companies specialize in the development, production, and distribution of advanced photonics, vision, and precision motion components and sub-assemblies. These highly engineered solutions are supplied to Original Equipment Manufacturers (OEMs) across the medical and industrial sectors.
- CEO
- Matthijs Glastra
- IPO
- 1999
- Employees
- 3,000
- HQ
- Bedford, MA, US
Get TickerSpark's AI analysis on NOVT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.86B
- P/E
- 76.11
- Fwd P/E
- 27.69
- PEG
- -8.61
- P/S
- 3.55
- P/B
- 2.67
- EV/EBITDA
- 28.97
- Div Yield
- 0.00%
- Gross Margin
- 43.20%
- Op Margin
- 8.54%
- Net Margin
- 4.89%
- ROE
- 3.62%
- ROIC
- 2.59%
Latest fiscal year · YoY change
- Revenue
- $980.60M+3.3%
- Gross Profit
- $407.81M-3.3%
- Op Income
- $116.66M
- Net Income
- $53.83M-16.0%
- EPS
- $1.47-17.4%
- OCF Growth
- -59.6%
- FCF Growth
- -65.7%
- 52W High
- $176.38
- 52W Low
- $99.42
- 50D MA
- $137.79
- 200D MA
- $141.72
- Beta
- 1.70
- RSI (14)
- 31
- Avg Volume
- 441.11K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Novanta reported a strong Q3 with revenue, EBITDA, EPS, bookings, and backlog all ahead of expectations, while also closing Riverpoint Medical and guiding to continued growth despite a temporary Stockport manufacturing headwind.· November 10, 2026
- Revenue rose 23% reported to $305 million, with nearly 10% organic growth and the strongest organic growth in more than three years.
- Adjusted EBITDA increased 38% to $80 million, with margin reaching 26%, the highest in company history.
- Adjusted EPS was $1.05, up 21% year over year; bookings rose 29% and backlog ended at $543 million.
- Riverpoint Medical contributed about $33 million in the quarter and is integrating in line with expectations.
- Management flagged a temporary gross margin hit from the U.K. Stockport issue and factory moves, but said the company is on track for 2027 margin expansion.
Novanta reported third-quarter 2026 revenue of $305 million, up 23% reported, with organic growth of nearly 10%. Adjusted EBITDA was $80 million, up 38% year over year, with a 26% margin, up 290 basis points. Adjusted EPS was $1.05, up 21% year over year. Adjusted gross profit was $143 million, or a 47% adjusted gross margin, versus $115 million and 46.5% a year ago. Bookings grew 29%, backlog was $543 million, and year-to-date operating cash flow was $156 million. For Q4 2026, management guided to revenue of about $306 million to $312 million, adjusted EBITDA of $76 million to $79 million, and adjusted EPS of $0.91 to $0.96. For full-year 2026, they raised revenue guidance to about $1,135 million to $1,140 million, expect organic growth of about 7% and reported growth of about 16%, adjusted gross margin of about 46.5%, adjusted EBITDA of $274 million to $277 million, adjusted EPS of $3.66 to $3.71, and operating cash flow of about $200 million.
Matthijs Glastra framed the quarter as evidence that Novanta’s strategy is working: “more medical, more recurring, and less cyclical.” He emphasized the company’s proprietary technologies across robotics, fluid management, laser beam steering, and embedded software, and said these competencies support durable growth in healthcare and advanced industrial markets. His tone was confident but measured, acknowledging the Stockport issue and calling it a temporary setback while stressing strong demand, a large backlog, and optimism for 2027.
Robert Buckley highlighted the financial upside from both organic execution and Riverpoint, citing Q3 adjusted gross margin of 47%, adjusted EBITDA of $80 million, and operating cash flow of $39 million, with year-to-date operating cash flow of $156 million. He said the company funded the $1.2 billion Riverpoint purchase with borrowings, equity proceeds, and cash, ending Q3 with $839 million of gross debt, $149 million of cash, and net leverage of 2.2x. He also noted the company expects about $200 million of operating cash flow for 2026, year-end gross debt of about $818 million, and full-year adjusted gross margin of about 46.5% due to the temporary Stockport headwind.
Analysts focused on the Stockport manufacturing issue, asking what happened, how large the gross margin impact is, and whether it could spill into 2027. Management said a major end-user test identified an issue, shipments are paused while the company corrects it, and they expect to restart shipments in the first quarter; Buckley estimated roughly a 200 basis point impact in Q4, with margin recovery starting in Q1 and more improvement by Q2. Questions also covered the 2027 margin bridge, where management said the main drivers are resolving Stockport, removing redundant factory costs, and benefiting from Riverpoint mix. Analysts also asked about air bearing spindles growth and SG&A; management said the business is sold out for two years and should fill capacity by 2028, while Q4 SG&A should be slightly above Q3 with only a modest R&D uptick.
The call showed strong demand across key end markets, with 29% bookings growth, a $543 million backlog, and new product revenue up 23% in the quarter. Management believes Riverpoint adds a more recurring medical mix and that 2027 should benefit from a full year of Riverpoint, less manufacturing disruption, and continued new product momentum.
Management openly acknowledged a temporary but meaningful gross margin headwind from the Stockport production slowdown and related factory move costs, with Q4 gross margin expected to be about 46% versus an earlier expectation of 48%. Precision medicine revenue also declined 5% year over year due to a deliberate exit from lower-margin business and weaker life-sciences demand, and the company said some recovery depends on resolving testing and shipment issues and lapping the current disruption.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.3%
- Shares Outstanding
- 37.82M
- Float Shares
- 37.56M
of shares held by institutions
409 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for NOVT, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | May 18, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Nov 13, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Aug 4, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jul 22, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jul 25, 22 | Filing → |
| Gilbert CisnerosHouse · CA39 | Buy | Oct 22, 19 | Filing → |
| Gilbert CisnerosHouse · CA39 | Buy | Aug 1, 19 | Filing → |
| Gilbert CisnerosHouse · CA39 | Buy | May 22, 19 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Apr 15, 19 | Filing → |
| Gilbert CisnerosHouse · CA39 | Buy | Apr 17, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 4.93M | ▲ 133.31K |
| Vanguard Group Inc | 4.34M | ▼ 38.19K |
| Vanguard Portfolio Management LLC | 2.41M | ▲ 18.40K |
| Price T Rowe Associates Inc | 2.06M | ▼ 167.13K |
| Vanguard Capital Management LLC | 1.70M | ▲ 90.15K |
| Allspring Global Investments Holdings, LLC | 1.64M | ▼ 173.35K |
| State Street Corp | 1.48M | ▲ 43.26K |
| Wasatch Advisors LP | 1.05M | ▲ 292.12K |
| Geode Capital Management, LLC | 1.03M | ▲ 40.77K |
| Congress Asset Management Co | 979.84K | ▲ 6.08K |
| Gw&K Investment Management, LLC | 899.31K | ▲ 2.04K |
| Goldman Sachs Group Inc | 892.64K | ▲ 516.73K |
Held by 339 ETFs
Biggest fund positions in NOVT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 3, 26 | FARRELL MATTHEW | other | 241 |
| Nov 3, 26 | FARRELL MATTHEW | other | 241 |
| Sep 11, 26 | Secor Thomas N | sell | 663 |
| Jul 2, 26 | Glastra Matthijs | sell | 3,024 |
| Jul 2, 26 | Glastra Matthijs | sell | 1,672 |
| Jul 2, 26 | Glastra Matthijs | sell | 1,167 |
| Jul 2, 26 | Glastra Matthijs | sell | 437 |
| Jul 2, 26 | Glastra Matthijs | sell | 200 |
| Jun 2, 26 | Glastra Matthijs | sell | 38 |
| Jun 2, 26 | Glastra Matthijs | sell | 500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NOVT coverage
Recent articles, reports, and earnings notes.
No research on NOVT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NOVT report →Novanta Inc. (NOVT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
What Novanta (NOVT) Said on Its Q3 Earnings Call
marketbeat.com · Nov 10
Novanta to Present at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026
businesswire.com · Nov 10
Novanta (NOVT) Q3 Earnings and Revenues Surpass Estimates
zacks.com · Nov 9
Novanta Announces Financial Results for the Third Quarter 2026
businesswire.com · Nov 9
Baron Discovery Fund Q3 2026 Portfolio Activity
seekingalpha.com · Nov 4
Human Data, Robot Hands: Where Automation Goes Next
etftrends.com · Oct 21
Novanta to Present at the Baird 2026 Global Industrial Conference on Wednesday, November 11, 2026
gurufocus.com · Oct 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.